
DexCom (DXCM) Stock Forecast & Price Target
DexCom (DXCM) Analyst Ratings
Bulls say
DexCom is expected to have several upside drivers in the future, including the 15-day rollout and international Stelo for automatic insulin delivery, as well as potential coverage of T2NIT by CMS in the US. With strong 1Q26 performance and bullish expectations for the future, the company remains positioned for growth and positive financials despite recent controversy and market fluctuations.
Bears say
DexCom is experiencing slowing growth in the US market, while also facing stiff competition from leading competitor Abbott Laboratories. Additionally, there are concerns about DexCom's ability to secure coverage for its CGM systems from insurance providers, which could impact future revenue. Despite the company's strong momentum in international markets and expansion into integration with insulin pumps, there is still a level of uncertainty surrounding DexCom's ability to continue its growth trajectory.
This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.
DexCom (DXCM) Analyst Forecast & Price Prediction
Start investing in DexCom (DXCM)
Order type
Buy in
Order amount
Est. shares
0 shares